Clinical Trials | May 02, 2023
Lilly's Lebrikizumab shows improved face or hand dermatitis
Lebrikizumab is an investigational high-affinity and potent IL-13 inhibitor being studied in adult and adolescent patients
Lebrikizumab is an investigational high-affinity and potent IL-13 inhibitor being studied in adult and adolescent patients
The appointment is effective from May 01, 2023 for five years
The YP-P10 pre-clinical head-to-head study, jointly conducted by five people including Dr. Kyungho Park of Naason Science
The funding will be used to expand the product line for remote patient monitoring and to scale the business across Asia and Africa
Malaria is a life-threatening parasitic infection that is spread by the bites of mosquitoes carrying the Plasmodium parasite
Everest and SPH Kyuan will work closely to promote import and channel distribution of XERAVA in China
Franson will help biopharma clients design a phased approach to inform and execute clinical development plans
Clinical Decision Support Systems' huge potential to help ensure that each patient can receive high-quality care; study shows a reduction in diagnostic errors from 24% to 2%
India's strategy against Covid was more effective than any other countries in the world
MoU signed between AIIA and University of Amrita Vishwa Vidhyapeetham for collaboration in the field of Research and Academics in Ayurveda
Subscribe To Our Newsletter & Stay Updated
